Fig. 3
From: Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients
Kaplan-Meier analysis of the impact of ALCAM expression in primary tumors in melanoma patients without regional lymph node metastases (a, b) and in patients with negative SLNB status (c, d). Survival analysis showed that in patients without locoregional nodal metastases increased ALCAM expression (IRS) is associated with shorter CSOS (a) and DFS (b); similarly, also in SLNB-negative patients, increased ALCAM expression (IRS) was related to shorter CSOS (c) and DFS (d)